International journal of gastrointestinal cancer最新文献

{"title":"Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.","authors":"A William Blackstock,&nbsp;Joel E Tepper,&nbsp;Donna Niedwiecki,&nbsp;Donna R Hollis,&nbsp;Robert J Mayer,&nbsp;Margaret A Tempero","doi":"10.1385/ijgc:34:2-3:107","DOIUrl":"https://doi.org/10.1385/ijgc:34:2-3:107","url":null,"abstract":"<p><strong>Purpose: </strong>Determine the safety and efficacy of twice weekly gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with surgically staged, locally advanced pancreatic cancer.</p><p><strong>Methods: </strong>Patients with surgically staged, locally advanced, nonmetastatic adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice weekly (40 mg/m2/d) for 5 wk concurrent with upper abdominal radiation (50.4 Gy in 180 cGy daily fractions over 5.5 wk). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000 mg/m2) weekly for five cycles. Each cycle consisted of 3 wk of treatment followed by 1 wk without treatment. Disease progression and response were assessed at 6- to 8-wk intervals.</p><p><strong>Results: </strong>From February through December 1999, 43 patients were entered into this phase II trial, 39 of whom were evaluable for treatment response. The median age was 59 yr (range: 39-84 yr); there were 18 males (47%) in the study. Grade III and IV hematologic toxicity occurred in 48 and 21% of patients, respectively, and was primarily leukocytopenia and neutropenia. Grade III and IV gastrointestinal toxicities occurred in 31 and 10% of patients, respectively. There was one death attributed to sepsis. The concurrent gemcitabine and radiation portion of the study was completed without treatment interruptions in 56% of patients. The overall median survival was 8.2 mo and the median survival in the 44% of patients demonstrating a sustained CA-19-9 response was 13.5 mo. Only six patients experienced local regional progression as their first site of failure. Two patients (5%) were still alive at 35 and 41 mo posttreatment.</p><p><strong>Conclusions: </strong>These results confirm the feasibility of twice weekly gemcitabine and radiation for the treatment of pancreatic cancer. Although this treatment strategy produced good local regional control, this did not result in a survival advantage. Stratifying patients by performance status and CA-19-9 response in future trials may be of value.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"34 2-3","pages":"107-16"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/ijgc:34:2-3:107","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24676532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiogenesis and antiangiogenic strategies in pancreatic cancer.","authors":"William E Fisher,&nbsp;David H Berger","doi":"10.1385/IJGC:33:1:79","DOIUrl":"https://doi.org/10.1385/IJGC:33:1:79","url":null,"abstract":"<p><p>Despite numerous advances in the treatment of solid tumors, the prognosis of patients diagnosed with pancreatic cancer remains dismal. Results of both surgical and non-surgical treatment for pancreatic cancer have been extremely disappointing because of the tumors propensity to metastasize, failure of chemotherapy to achieve adequate levels within the tumor, and resistance of pancreatic cancer to cytotoxic agents. Current chemotherapeutic agents and radiation treatments rely on the rapidly dividing nature of tumor cells and are limited by their cytotoxic effects on normal cells. The need to exploit the difference between normal and malignant cells has resulted in an enormous amount of research into the process of tumor neovascularization. New agents are currently being developed that block tumor growth and metastasis through inhibition of angiogenesis. This article reviews the process of angiogenesis and antiangiogenic strategies with a special emphasis on pancreatic cancer.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"33 1","pages":"79-88"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:33:1:79","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22523473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NF-kappaB in pancreatic cancer.","authors":"Guido M Sclabas,&nbsp;Shuichi Fujioka,&nbsp;Christian Schmidt,&nbsp;Douglas B Evans,&nbsp;Paul J Chiao","doi":"10.1385/IJGC:33:1:15","DOIUrl":"https://doi.org/10.1385/IJGC:33:1:15","url":null,"abstract":"<p><p>Although the genetic profile of pancreatic cancer is emerging as a result of much research, the role of specific genetic alterations that initiate tumorigenesis and produce its cardinal clinical features of locally aggressive growth, metastasis, and chemotherapy resistance remains unresolved. Recently, a number of studies have shown that the inhibition of constitutive NF-kappaB activation, one of the frequent molecular alterations in pancreatic cancer, inhibits tumorigenesis and metastasis. It also sensitizes pancreatic cancer cell lines to anticancer agent-induced apoptosis. Therefore because of the crucial role of NF-kappaB in pancreatic cancer, it is a potential target for developing novel therapeutic strategies for the disease. In vivo and in vitro models that mimic the tumorigenic phenotypes in the appropriate histological and molecular concert would be very useful for confirming the suspected role of the pancreatic cancer signature genetic lesions and better understanding the molecular basis of this disease.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"33 1","pages":"15-26"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:33:1:15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22523582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biliopancreatic fistula caused by an intraductal papillary-mucinous tumor of the pancreas confirmed by biochemical analysis of mucin.","authors":"Shuichi Sano,&nbsp;Isao Nishimori,&nbsp;Nobuto Okamoto,&nbsp;Takuhiro Kohsaki,&nbsp;Saburo Onishi,&nbsp;Masanori Morita,&nbsp;Keijiro Araki","doi":"10.1385/IJGC:34:2-3:101","DOIUrl":"https://doi.org/10.1385/IJGC:34:2-3:101","url":null,"abstract":"<p><p>Intraductal papillary-mucinous tumor of the pancreas is occasionally accompanied by biliopancreatic fistula. However, it is difficult to show the inflow of mucin produced by the tumor into the common bile duct. To confirm the biliopancreatic fistula, the mucin-rich fraction was purified from the bile and stained with antimucin antibodies. Western blot analysis showed characteristic smear staining patterns for mucin molecules with three types of antimucin antibodies. Immunohistochemical analysis with the antibody showed significant signals of the cancer cells and the luminal content of the dilated pancreatic duct. These results showed that the bile contained an abundance of mucin, which was produced by the primary pancreatic tumor. In cases with intraductal papillary-mucinous tumor of the pancreas, biochemical analysis of mucin molecules in the bile can be of clinical use in consideration of pathological process of tumor progression.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"34 2-3","pages":"101-6"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:34:2-3:101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24678277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epstein-Barr virus association is rare in esophageal squamous cell carcinoma.","authors":"Hideo Yanai,&nbsp;Atsuyoshi Hirano,&nbsp;Keisuke Matsusaki,&nbsp;Toyokazu Kawano,&nbsp;Osamu Miura,&nbsp;Tomoharu Yoshida,&nbsp;Kiwamu Okita,&nbsp;Norio Shimizu","doi":"10.1385/IJGC:33:2-3:165","DOIUrl":"https://doi.org/10.1385/IJGC:33:2-3:165","url":null,"abstract":"<p><strong>Background: </strong>A critical role of Epstein-Barr virus (EBV) in carcinogenesis of nasopharyngeal squamous cell carcinoma and gastric adenocarcinoma is strongly suspected. We analyzed the possible EBV association for Japanese squamous cell carcinoma (SCC)-dominant esophageal cancer cases.</p><p><strong>Methods: </strong>We retrospectively screened 36 surgically resected esophageal cancer lesions from 36 patients mainly with SCC using in situ hybridization (ISH) for EBV-encoded small RNA1 (EBER-1). EBV DNA analysis using real-time quantitative polymerase chain reaction (Q-PCR) was performed for three recent cases.</p><p><strong>Results: </strong>We found no EBER-1-positive cancer cell in any tested esophageal cancer lesion. There were many EBER-1-positive tumor-infiltrating lymphocytes in the basaloid SCC lesion and a small number of positive lymphocytes in the other five advanced SCC lesions (14.7% of SCC). One SCC lesion with a highcopy number of EBV DNA had EBER-1-positive lymphocytes.</p><p><strong>Conclusions: </strong>EBV is rarely associated with esophageal SCC, and may appear through tumorinfiltrating lymphocytes in some advanced lesions.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"33 2-3","pages":"165-70"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:33:2-3:165","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24158073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas.","authors":"Eleni E Carvounis,&nbsp;Vassilis Smyrniotis,&nbsp;Achilles Chatziioannou,&nbsp;Agatha Paphitis","doi":"10.1385/IJGC:33:2-3:103","DOIUrl":"https://doi.org/10.1385/IJGC:33:2-3:103","url":null,"abstract":"<p><p>Pure undifferentiated carcinoma with osteoclast-like giant cells of the pancreas is very rare. Its prognosis is grim. The clinicopathologic findings of a case of this unusual tumor are presented. Following resection, the patient at 9 mo follow-up developed local recurrence.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"33 2-3","pages":"103-6"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:33:2-3:103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24160427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of MUC5AC and MUC6 in invasive ductal carcinoma of the pancreas and relationship with prognosis.","authors":"Ma Jinfeng,&nbsp;Wataru Kimura,&nbsp;Ichiro Hirai,&nbsp;Fumiaki Sakurai,&nbsp;Toshiyuki Moriya,&nbsp;Masaomi Mizutani","doi":"10.1385/IJGC:34:1:09","DOIUrl":"https://doi.org/10.1385/IJGC:34:1:09","url":null,"abstract":"<p><strong>Aim/background: </strong>MUC5AC and MUC6 are two major types of mucin that are abundantly present in the stomach; both of them form a gel of high viscosity that provides protection and lubrication. Expressions of MUC5AC and MUC6 are seen in pancreatic neoplasms, whereas the relationships between MUC5AC/MUC6 expression and clinicopathological factors and patient prognosis in invasive ductal carcinoma (IDC) of the pancreas have not been investigated. The aim of this study was to investigate MUC5AC and MUC6 expressions in IDC with special reference to clinicopathological factors and patient prognosis.</p><p><strong>Methods: </strong>Tissue samples were taken from 33 patients with IDC of the pancreas after radical surgical treatment. MUC5AC and MUC6 expressions were examined immunohistochemically.</p><p><strong>Results: </strong>The expressions of MUC5AC and MUC6 were observed in the cytoplasm of the tumor cells. MUC5AC and MUC6 immunoreactivities in the cancer tissues were found in 21 (63.6%) and 15 (45.5%) of 33 cases of IDC of the pancreas, respectively. MUC5AC-negative expression was associated significantly with lymphatic invasion, venous invasion, lymph node metastasis, and MUC5AC-positive patients showed significant better survival than those MUC5AC-negative patients. MUC6 expression was significantly related to tumor location, whereas MUC6 expression did not show significant relationship with patient survival.</p><p><strong>Conclusion: </strong>The results indicate that MUC5AC expression plays an important role in impacting tumor progression in IDC of the pancreas. MUC5AC expression is a benefit to better survival of patients with IDC of the pancreas. MUC6 expression is not involved in tumor progression in IDC of the pancreas.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"34 1","pages":"9-18"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:34:1:09","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24598807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value and interobserver agreement of endoscopic ultrasonography for superficial squamous cell carcinoma of the esophagus: a prospective study.","authors":"Hideo Yanai,&nbsp;Toshiya Harada,&nbsp;Takeshi Okamoto,&nbsp;Atsuyoshi Hirano,&nbsp;Naori Takeo,&nbsp;Tomoharu Yoshida,&nbsp;Kiwamu Okita,&nbsp;Toyokazu Kawano","doi":"10.1385/IJGC:34:1:01","DOIUrl":"https://doi.org/10.1385/IJGC:34:1:01","url":null,"abstract":"<p><strong>Background and aims: </strong>Submucosal invasion of superficial esophageal cancer (SEC) is related to the prognosis. We prospectively analyzed outcomes of SEC in patients staged by endoscopic ultrasonography (EUS).</p><p><strong>Patients and methods: </strong>We staged 31 endoscopically diagnosed SEC cases using a 20/15-MHz thin probe. The EUS tumor stage was classified as EUSM (limited within mucosa), EUS-SM (with submucosal invasion), or EUS-MP over (invading the muscularis propria or deeper). Lymph node metastasis and 2-yr survival were analyzed according to the EUS tumor stage in 29 squamous cell carcinoma cases. Interobserver agreement of the EUS stage was tested between the examiner and a blind reviewer.</p><p><strong>Results: </strong>Lymph node metastasis was significantly frequent in the EUS-SM group (8 of 18 cases [44.4%]) compared with the EUS-M group (1 of 10 cases [10%]) (p = 0.03). Patient survival at 2 yr after initial therapy was 72.2% in the EUS-SM group and 90% in the EUS-M group. Death from cancer was noted only in the EUS-SM group (three cases). The accuracy rates of EUS tumor staging were 74.1% by the examiner and 66.7% by the blind reviewer, with moderate interobserver agreement (kappa = 0.46).</p><p><strong>Conclusions: </strong>Thin-probe EUS can classify SEC into two groups: the EUS-M group with excellent outcome and the EUS-SM group with a significant risk of lymph node metastasis.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"34 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:34:1:01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24598886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The challenge of pancreatic cancer.","authors":"James L Abbruzzese","doi":"10.1385/IJGC:33:1:1","DOIUrl":"https://doi.org/10.1385/IJGC:33:1:1","url":null,"abstract":"","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"33 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:33:1:1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22523580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel gene therapy approaches to pancreatic cancer.","authors":"Matthew H Katz,&nbsp;Michael Bouvet","doi":"10.1385/IJGC:33:1:89","DOIUrl":"https://doi.org/10.1385/IJGC:33:1:89","url":null,"abstract":"<p><p>One of the most lethal human malignancies, pancreatic adenocarcinoma has remained a therapeutic challenge. Historically, the only curable treatment modalities available to patients with this disease have included pancreaticoduodenectomy with adjuvant chemoradiation. Few patients, however, have resectable disease at the time of presentation, and even for those who are offered this radical course of treatment, post-surgical survival is dismally short. Recently, however, advances in the understanding of the molecular biology of pancreatic cancer have enabled researchers to investigate novel gene therapy approaches to the treatment of this disease. In this paper, we review the common genetic mutations found in pancreatic adenocarcinomas, discuss strategies for the manipulation of genetic targets, and assess current progress in the field of gene therapy as it relates to pancreatic cancer.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"33 1","pages":"89-97"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:33:1:89","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22523588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}